Condition
Atypical Facial Pain
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05257655Not ApplicableCompleted
Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius
NCT02024724Phase 4Completed
Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain
NCT01920087Phase 2WithdrawnPrimary
Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain
Showing all 3 trials